Search

Author/Creator Tang, Weifeng

1. Model‐based characterization of the relationship between dapagliflozin systemic exposure and HbA1c response in patients with type 1 diabetes mellitus. Issue 6 (14th March 2019)

Authors:
Parkinson, Joanna; Tang, Weifeng; Åstrand, Magnus; Melin, Johanna; Ekholm, Ella; Hamrén, Bengt; Boulton, David W.
Journal:
Diabetes, obesity & metabolism
Issue:
Volume 21:Issue 6(2019)
Page Start:
1381
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Bioequivalence of fixed‐dose combinations of dapagliflozin and metformin with single‐component tablets in healthy subjects and the effect of food on bioavailability. Issue 2 (20th October 2015)

Authors:
de Bruin, Tjerk W.A.; Reele, Stots; Hamer‐Maansson, Jennifer E.; Parikh, Shamik; Tang, Weifeng
Journal:
Clinical pharmacology in drug development
Issue:
Volume 5:Issue 2(2016:Mar./Apr.)
Page Start:
118
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Comparison of pharmacokinetics and the exposure–response relationship of dapagliflozin between adolescent/young adult and adult patients with type 1 diabetes mellitus. Issue 8 (20th June 2019)

Authors:
Busse, David; Tang, Weifeng; Scheerer, Markus; Danne, Thomas; Biester, Torben; Sokolov, Viktor; Boulton, David; Parkinson, Joanna
Journal:
British journal of clinical pharmacology
Issue:
Volume 85:Issue 8(2019)
Page Start:
1820
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗